c-Met (METor MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR; RTK class X, HGF receptor family). It was originally identified as an oncogene activated in vitro after treatment of a human osteogenic sarcoma (HOS) cell line[1]. Currently, c-Met receives great interest for its role of aberrant signaling in tumorigenesis, particularly in the development of the invasive and metastatic phenotypes (see also Axon 2240). Signaling via the Met–HGF/SF pathway has been shown to lead to a wide range of biological activities including proliferation (mitosis), scattering (motility), and branching morphogenesis, embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation[2].

[1] Molecular cloning of a new transforming gene from a chemically transformed human cell line. C.S. Cooper, M. Park, D.G. Blair et al. Nature 1984, 311, 29–33.
[2] M. Jeffers, L. Schmidt, N. Nakaigawa, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 1997, 94, 11445–11450.


17 Item(s)

per page
Axon ID Name Description From price
3946 Altiratinib Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases Inquire
1916 AMG 208 Inhibitor of c-MET receptor tyrosine kinase (RTK) €95.00
3945 AMG-337 Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met Inquire
2368 Amuvatinib RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met €105.00
1838 ARQ 197 c-MET tyrosine kinase Inhibitor €90.00
4040 BMS-777607 potent, selective and orally bioavailable c-Met inhibitor Inquire
1819 Cabozantinib S-malate Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 €60.00
3423 Capmatinib Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor €80.00
1660 Crizotinib c-MET Inhibitor; NPM-ALK inhibitor €70.00
1582 Foretinib c-MET and VEGFR2 tyrosine kinase inhibitor €90.00
1959 Golvatinib Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 €90.00
2553 LY 2801653 Orally bioavailable multi-kinase inhibitor with potent activity against c-MET €120.00
3975 MGCD265 dihydrochloride Orally active, potent MET/SMO dual inhibitor €130.00
1583 PF 04217903 mesylate c-MET tyrosine kinase Inhibitor €80.00
1914 SGX 523 ATP-competitive inhibitor of c-MET €120.00
1581 SU 11274 ATP-competitive inhibitor of c-MET €90.00
3864 Volitinib dihydrochloride ATP-competitive small molecule c-Met kinase inhibitor Inquire

17 Item(s)

per page
Please wait...